Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses challenges with a trial conducted by Tata Memorial Hospital seeking to solidify the impact of concomitant chemoradiation with FIGO stage IIIb squamous cervical cancer (NCT00193791).

The study arm of chemoradiation has the potential to improve the survival by 10%. In the study arm, apart from the standard radiotherapy treatment, patients received weekly chemotherapy injections during external radiation therapy. The study arm is associated with additional 5% acute hematological and gastrointestinal toxicities, which are treatable with medications, blood transfusions, and modifications in the ongoing treatment.

Running this trial in developing countries was a challenge, says Mahantshetty, since this trial costs a lot in terms of infrastructure. Since some patients lived in far remote places, following these patients was a challenge, explains Mahantshetty. Compliance to receive concomitant chemotherapy was an additional challenge.

This trial has been implemented in routine care, says Mahantshetty, and the compliance to follow-up after receiving treatment has helped develop good outcome data.

Videos

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses challenges with a trial (NCT00193791) conducted by Tata Memorial Hospital seeking to solidify the impact of concomitant chemoradiation with FIGO stage IIIb squamous cervical cancer.

Dr. Mahantshetty on Challenges With Concomitant Chemoradiation Trial in Cervical Cancer

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, India, discusses unmet needs for patients with cervical cancer.

Cervical cancer is a major health problem in developing countries. According to Mahantshetty, an unmet need is the ability to treat the patients optimally so that their outcomes are improved.

Trials are ongoing to determine how to best improve outcomes in women, particularly those in developing countries, says Mahantshetty.

Dr. Mahantsetty on Unmet Needs in Cervical Cancer

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses chemoradiation in patients with cervical cancer.

Mahantshetty says that many women with cervical cancer present at an advanced stage, so a trial was designed to see if chemoradiation would be beneficial to this particular population.

In a trial conducted by Tata Memorial Hospital, investigators sought to solidify the impact of concomitant chemoradiation in women with FIGO stage IIIb squamous cell cervical cancer.

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses chemoradiation in patients with cervical cancer.
 

Dr. Mahantshetty Discusses Chemoradiation in Cervical Cancer

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses the results of a trial of chemoradiation in patients with cervical cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

In a trial of patients with stage IIIB squamous cell carcinoma of the uterine cervix, cisplatin chemoradiation and radiation were compared. The aim was to see whether chemoradiation was beneficial in this population.

An absolute benefit of 8% and 8.5% for disease-free survival and overall survival was observed in the chemoradiation arm.

Umesh Mahantshetty, MD, MBBS

Articles

Dr. Mahantshetty on Challenges With Concomitant Chemoradiation Trial in Cervical Cancer

Dr. Mahantsetty on Unmet Needs in Cervical Cancer

Dr. Mahantshetty Discusses Chemoradiation in Cervical Cancer

Dr. Mahantshetty Discusses Results of Chemoradiation in Cervical Cancer